Avenue therapeutics announces regulatory update based on type c meeting with fda and next steps in the development of iv tramadol

Miami, april 17, 2023 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue” or the “company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it has received official meeting minutes from the type c meeting with the u.s. food and drug administration (“fda”) conducted on march 9, 2023, regarding the development of intravenous (“iv”) tramadol for the treatment of post-operative pain. the purpose of this meeting was to discuss and reach agreement with the fda on the proposed study protocol that would assess the risk of opioid-induced respiratory depression related to opioid stacking on iv tramadol compared to iv morphine.
ATXI Ratings Summary
ATXI Quant Ranking